GGrantIndex
← Leaderboards

Tippi Mackenzie

University Of California, San Francisco

$11,944,783
Attributed
$11,944,783
Total exposure
6
Grants
5
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $2.2M · FY201025
$2.5M$1.9M$1.3M$625K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$11,944,783 · 6

By mechanism

R01$11,388,311 · 4
K08$517,240 · 1
F32$39,232 · 1

Top collaborators

No co-investigators on record.

Most similar at University Of California, San Francisco

Same institution · by research overlap

Others in their field

Top investigators on “Fetal

Research focus

FetalImmune ResponsePregnancyPostnatalFetusCellsMouse ModelBasePhenotypeLifeMothersAllogenicResponsePreventInsightRegulatory T-LymphocyteImmuneImmunologicsT-LymphocyteAntigensMediatingAffectImmune SystemIn Utero

Grant awards (24)

Developing gene therapy strategies to treat alpha thalassemia$697,241
R01 · FY2025 · HL · contact PI
Phase 1 Study of In Utero Enzyme Replacement Therapy for the Treatment of Lysosomal Storage Diseases$663,680
R01 · FY2025 · HD · contact PI
Developing gene therapy strategies to treat alpha thalassemia$690,110
R01 · FY2024 · HL · contact PI
Phase 1 Study of In Utero Enzyme Replacement Therapy for the Treatment of Lysosomal Storage Diseases$658,363
R01 · FY2024 · HD · contact PI
Autoimmune Regulator gene (Aire)-mediated tolerance to pregnancy-associated self-antigens$771,699
R01 · FY2023 · AI · contact PI
Developing gene therapy strategies to treat alpha thalassemia$710,975
R01 · FY2023 · HL · contact PI
Phase 1 Study of In Utero Enzyme Replacement Therapy for the Treatment of Lysosomal Storage Diseases$666,314
R01 · FY2023 · HD · contact PI
Autoimmune Regulator gene (Aire)-mediated tolerance to pregnancy-associated self-antigens$782,116
R01 · FY2022 · AI · contact PI
Developing gene therapy strategies to treat alpha thalassemia$723,621
R01 · FY2022 · HL · contact PI
Phase 1 Study of In Utero Enzyme Replacement Therapy for the Treatment of Lysosomal Storage Diseases$681,906
R01 · FY2022 · HD · contact PI
Autoimmune Regulator gene (Aire)-mediated tolerance to pregnancy-associated self-antigens$788,850
R01 · FY2021 · AI · contact PI
Autoimmune Regulator gene (Aire)-mediated tolerance to pregnancy-associated self-antigens$790,304
R01 · FY2020 · AI · contact PI
Autoimmune Regulator gene (Aire)-mediated tolerance to pregnancy-associated self-antigens$781,986
R01 · FY2019 · AI · contact PI
T cell activation and the breakdown of maternal-fetal tolerance in preterm labor$396,250
R01 · FY2019 · AI · contact PI
T cell activation and the breakdown of maternal-fetal tolerance in preterm labor$396,250
R01 · FY2018 · AI · contact PI
T cell activation and the breakdown of maternal-fetal tolerance in preterm labor$396,250
R01 · FY2017 · AI · contact PI
T cell activation and the breakdown of maternal-fetal tolerance in preterm labor$396,250
R01 · FY2016 · AI · contact PI
T cell activation and the breakdown of maternal-fetal tolerance in preterm labor$396,146
R01 · FY2015 · AI · contact PI
Maternal and fetal immune responses to in utero HSC transplantation$71,105
K08 · FY2014 · AI · contact PI
Maternal and fetal immune responses to in utero HSC transplantation$71,105
K08 · FY2013 · AI · contact PI
Maternal and fetal immune responses to in utero HSC transplantation$125,010
K08 · FY2012 · AI · contact PI
Maternal and fetal immune responses to in utero HSC transplantation$125,010
K08 · FY2011 · AI · contact PI
Maternal and fetal immune responses to in utero HSC transplantation$125,010
K08 · FY2010 · AI · contact PI
IN UTERO MESENCHYMAL STEM CELL TRANSPLANTATION$39,232
F32 · FY2000 · HL